PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.

Reported: July 16, 2025 Initiated: June 30, 2025 #D-0511-2025

Product Description

Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Details

Units Affected
12,242 30-count bottles
Distribution
U.S. Nationwide
Location
Berkeley Heights, NJ

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.. Recalled by Breckenridge Pharmaceutical, Inc.. Units affected: 12,242 30-count bottles.
Why was this product recalled?
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Which agency issued this recall?
This recall was issued by the FDA Drug on July 16, 2025. Severity: Moderate. Recall number: D-0511-2025.